Although small- and medium-sized biotechs are absent from the
new Accelerating Medicines Partnership with industry and not-for-profit
organizations, consortium leaders expect that making results publicly available
on their search for new targets and biomarkers in four diseases will benefit
all players. However, it is unclear whether the $230 million, 5-year fund is
adequately financed to meet the partnership's goal of accelerating target
to Zerhouni, the idea for AMP was seeded many years ago when the NIH concluded
that something needed to be done to speed the development of new drugs.
said that it was important to have multiple companies in AMP engaged in each
disease area. "Once you have five to six companies, you get a diversity of
opinions that adds texture and wisdom," he said.
precise contribution of each organization has not been disclosed, but on
average each company will give $1-2 million per year. The average annual
R&D budget of the participating companies is about $5 billion.
to Wholley, there are three tracks for distributing AMP funds.
Fishburn, C.S. SciBX 7(8);
doi:10.1038/scibx.2014.215 Published online Feb. 27, 2014
1. Cain, C. BioCentury
20(45), A8-A10; Nov. 5, 2012
American Diabetes Association, Alexandria, Va.
Biogen Idec Inc.
(NASDAQ:BIIB), Weston, Mass.
Food and Drug Administration, Silver Spring, Md.
Foundation for the National Institutes of Health, Bethesda, Md.
Geoffrey Beene Foundation Alzheimer's Initiative, Washington, D.C.
Innovative Medicines Initiative, Brussels, Belgium
Lupus Foundation of America Inc., Washington, D.C.
Institutes of Health,
Pharmaceutical Research and Manufacturers of America, Washington, D.C.
(SIX:ROG; OTCQX:RHHBY), Basel, Switzerland
(Euronext:SAN; NYSE:SNY), Paris, France
USAgainstAlzheimer's, Washington, D.C.